Nkarta(US:NKTX)2025-11-10 21:13Financial Performance - Nkarta reported a cash balance of $316.5 million as of September 30, 2025, expected to fund operations into 2029[6] - Research and development (R&D) expenses for Q3 2025 were $20.2 million, while general and administrative (G&A) expenses were $7.1 million[10] - The net loss for Q3 2025 was $21.7 million, or $0.29 per basic and diluted share[10] - Total operating expenses for Q3 2025 were $27.3 million, compared to $33.8 million in Q3 2024[23] - Nkarta's total assets as of September 30, 2025, were $427.2 million, down from $501.2 million at the end of 2024[25] - Non-cash stock-based compensation included in R&D expenses was $0.5 million for Q3 2025[10] Clinical Development - Enrollment is underway in the second dose-escalation cohort for the NKX019 clinical program, with deep B-cell depletion observed in all patients treated to date[6] - Initial data for NKX019 in multiple autoimmune indications is expected to be presented at a medical conference in 2026[6] - Nkarta is evaluating NKX019 in multiple autoimmune conditions, including lupus nephritis and systemic sclerosis[15] - The company streamlined enrollment across its Ntrust-1 and Ntrust-2 clinical trials under a combined independent Data Safety Monitoring Board (iDSMB)[6]